[Pre-treatment and treatment-induced neuron-specific enolase in patients with small-cell lung cancer: an open prospective study]. / Valores pretratamiento e inducidos por el tratamiento de enolasa específica de neurona en pacientes con cáncer de pulmón microcítico: estudio prospectivo, abierto.

BACKGROUND: Neuron-specific enolase (NSE) is the most sensitive tumor marker for small-cell lung carcinoma (SCLC) at the time of diagnosis. The main purpose of this study was to review the usefulness of serum NSE level as a prognostic factor in patients with SCLC and to determine the correlation between the NSE level and the stage of disease and response to chemotherapy. METHODS: In this prospective study, patients with SCLC were evaluated for response to chemotherapy, survival without disease progression, and overall survival. The end point was designated at patient death due to SCLC. NSE assays were performed before and after completion of chemotherapy. RESULTS: Sixty-five patients were included in study. NSE levels were significantly higher in patients who died of SCLC. The pre-treatment NSE levels in patients who responded to treatment were significantly lower. The post-treatment NSE levels were not significantly correlated with response to chemotherapy, progression-free survival, overall survival, and prognosis of patients. Change in the NSE level between the pre- and post-treatment periods was not significantly correlated with response to treatment, progression-free survival, and overall survival. CONCLUSIONS: NSE levels might not be related with the stage of the disease. However, a low pre-treatment NSE level might be used in predicting good response to chemotherapy in patients with SCLC. The post-treatment serum NSE levels and the rate of change between pre- and post-treatment serum levels of NSE were not related with response to chemotherapy, progression-free survival, and overall survival.

Valor pronóstico del receptor del factor de crecimiento epitelial, factor de crecimiento endotelial vascular, E-cadherina, y p120 catenina en el carcinoma de pulmón no microcítico resecado / Prognostic Value of Epithelial Growth Factor Receptor, Vascular Endothelial Growth Factor, E-Cadherin, and p120 Catenin in Resected Non-Small Cell Lung Carcinoma

Introducción: Para predecir el pronóstico del cáncer de pulmón se han investigado varios marcadores. Enel presente estudio, mediante inmunohistoquímica se investigaron los valores pronósticos de la expresióndel receptor del factor de crecimiento epitelial (EGFR), factor de crecimiento endotelial vascular (VEGF),E-cadherina y p120 catenina en pacientes con un carcinoma de pulmón no microcítico (CPNM) sometidosa resección quirúrgica.Pacientes y métodos: Se determinó prospectivamente la expresión de EGFR, VEGF, E-cadherina y p120catenina en muestras resecadas de pacientes con CPNM que se habían sometido a cirugía entre 2003 y2007. Se registraron las características generales de los pacientes y relacionadas con la enfermedad y latasa de supervivencia.Resultados: En el estudio se incluyeron 170 pacientes con una edad media de 61,3 años. Después de unseguimiento medio de 27,5 meses, se determinó que la supervivencia mediana era de 44,0 meses y latasa de supervivencia a 5 años era del 46,2%. En los grupos con una tinción negativa y positiva, la tasa desupervivencia a los 5 años fue la siguiente: 32 y 66,7% para la expresión de EGFR (p = 0,02), 37,8 y 50,7%para la de VEGF (p = 0,5), 41 y 66% para la de E-cadherina (p = 0,19), 46 y 50% para la de p120 catenina(p = 0,27). El grado de diferenciación del tumor, estado de N, estadio y tinción de EGFR fueron variablesque afectaron significativamente a la supervivencia (p = 0,001, 0,006, 0,03 y 0,02, respectivamente). Enel análisis multivariante de Cox, el nivel de tinción de EGFR y el estado de N fueron las variables queafectaron significativamente a la supervivencia (p = 0,021 y p = 0,010).Conclusiones: Aunque la tinción negativa de EGFR se relacionó con una supervivencia desfavorable, latinción de VEGF, E-cadherina y p120 catenina no se ha relacionado con la supervivencia en pacientes conCPNM resecado(AU)

Introduction: Several markers have been investigated to predict the prognosis of lung cancer. In the presentstudy, the prognostic values of epithelial growth factor receptor (EGFR), vascular endothelial growthfactor (VEGF), E-cadherin, and p120 catenin expression were investigated by immunohistochemistry inpatients with a surgically resected non-small cell lung carcinoma (NSCLC).Patients and method: EGFR, VEGF, E-cadherin, and p120 catenin expression were prospectively determinedin resected specimens from patients with NSCLC who had undergone surgery between 2003 and 2007. Patients’ and disease-related general characteristics and survival rate were recorded. Results: One hundred seventeen patients with a mean age of 61.3 years were included in the study. Aftera mean follow-up of 27.5 months, the median survival was determined to be 44.0 months and the 5-yearsurvival was 46.2%. The 5-year survival in negative and positive staining groups were as follows; 32% and66.7% for EGFR (p = 0.02), 37.8% and 50.7% for VEGF (p = 0.5), 41% and 66% for E-cadherin (p = 0.19), 46%and 50% for p120 catenin (p = 0.27). The differentiation, N status, stage and EGFR staining were variablessignificantly affecting survival (p = 0.001, 0.006, 0.03 and 0.02 respectively). In multivariate Cox analysis,the EGFR staining level and N status were variables those significantly affecting survival (p = 0.021 andp = 0.010).Conclusions: While negative staining of EGFR was related with poor survival, staining of VEGF, E-cadherin,and p120 catenin were not related with survival in patients with resected NSCLC(AU)